Vilastobart is under clinical development by Xilio Therapeutics and currently in Phase II for Gastric Cancer. According to GlobalData, Phase II drugs for Gastric Cancer have a 28% phase transition ...
Telisotuzumab adizutecan is under clinical development by AbbVie and currently in Phase I for Gastric Cancer. According to GlobalData, Phase I drugs for Gastric Cancer have a 74% phase transition ...